Sprint Bioscience presents new preclinical data on DCPS at the AACR Annual Meeting 2026
18 mars, 07:45
Sprint Bioscience AB (publ) today announces that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA.
The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML.
The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.
The AACR Annual Meeting is one of the world’s most prominent scientific conferences in cancer research, bringing together leading researchers, clinicians, and drug developers. More information about the conference is available on AACR’s official website: https://www.aacr.org/meeting/aacr-annual-meeting-2026/
For further information, kindly contact:
Johan Emilsson, CEO, Sprint Bioscience
Phone: +46 (8) 411 44 55
Email: johan.emilsson@sprintbioscience.com
About Sprint Bioscience AB (publ)
Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs enter partnerships through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the pre-clinical phase and the company has successfully formed several agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.
Attachments
Sprint Bioscience presents new preclinical data on DCPS at the AACR Annual Meeting 2026
Ämnen i artikeln
Sprint Bioscience presents new preclinical data on DCPS at the AACR Annual Meeting 2026
18 mars, 07:45
Sprint Bioscience AB (publ) today announces that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA.
The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML.
The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.
The AACR Annual Meeting is one of the world’s most prominent scientific conferences in cancer research, bringing together leading researchers, clinicians, and drug developers. More information about the conference is available on AACR’s official website: https://www.aacr.org/meeting/aacr-annual-meeting-2026/
For further information, kindly contact:
Johan Emilsson, CEO, Sprint Bioscience
Phone: +46 (8) 411 44 55
Email: johan.emilsson@sprintbioscience.com
About Sprint Bioscience AB (publ)
Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs enter partnerships through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the pre-clinical phase and the company has successfully formed several agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.
Attachments
Sprint Bioscience presents new preclinical data on DCPS at the AACR Annual Meeting 2026
Ämnen i artikeln
Analys
Svensk ekonomi
Aktierekommendationer
Bolidens ras
H&M
Analys
Svensk ekonomi
Aktierekommendationer
Bolidens ras
H&M
Marknadsöversikt
1 DAG %
Senast
1 mån
